| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Mantle-Cell | 1 | 2023 | 29 | 0.780 |
Why?
|
| Machine Learning | 5 | 2025 | 325 | 0.690 |
Why?
|
| Aftercare | 1 | 2021 | 151 | 0.660 |
Why?
|
| Mouth Diseases | 1 | 2020 | 15 | 0.660 |
Why?
|
| Delirium | 3 | 2025 | 66 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2018 | 477 | 0.570 |
Why?
|
| Microtubule Proteins | 1 | 2018 | 28 | 0.560 |
Why?
|
| Acetyltransferases | 1 | 2018 | 72 | 0.560 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 49 | 0.560 |
Why?
|
| Microtubules | 1 | 2018 | 118 | 0.540 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2024 | 1170 | 0.490 |
Why?
|
| Clinical Deterioration | 2 | 2025 | 14 | 0.450 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 207 | 0.440 |
Why?
|
| Geriatric Assessment | 2 | 2025 | 182 | 0.420 |
Why?
|
| Periprosthetic Fractures | 2 | 2024 | 11 | 0.420 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 185 | 0.410 |
Why?
|
| Aged | 24 | 2025 | 20344 | 0.370 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2397 | 0.350 |
Why?
|
| Electronic Health Records | 4 | 2025 | 781 | 0.340 |
Why?
|
| Middle Aged | 25 | 2025 | 27697 | 0.330 |
Why?
|
| Inpatients | 2 | 2025 | 541 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 576 | 0.300 |
Why?
|
| Mass Screening | 2 | 2025 | 802 | 0.300 |
Why?
|
| Influenza, Human | 1 | 2015 | 674 | 0.300 |
Why?
|
| Adult | 22 | 2025 | 30410 | 0.300 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 6668 | 0.300 |
Why?
|
| Humans | 47 | 2025 | 126753 | 0.300 |
Why?
|
| Heart Failure | 1 | 2021 | 2289 | 0.290 |
Why?
|
| Hospitalization | 6 | 2024 | 1874 | 0.270 |
Why?
|
| Pneumonia | 2 | 2023 | 334 | 0.260 |
Why?
|
| Transplantation, Autologous | 3 | 2024 | 265 | 0.250 |
Why?
|
| Male | 28 | 2025 | 62543 | 0.240 |
Why?
|
| Smad2 Protein | 2 | 2016 | 51 | 0.240 |
Why?
|
| Retrospective Studies | 16 | 2025 | 17005 | 0.230 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2025 | 14 | 0.220 |
Why?
|
| Sulfides | 1 | 2024 | 25 | 0.220 |
Why?
|
| Neovascularization, Physiologic | 2 | 2017 | 199 | 0.220 |
Why?
|
| Cyclopropanes | 1 | 2024 | 72 | 0.220 |
Why?
|
| Acetates | 1 | 2024 | 80 | 0.210 |
Why?
|
| Delayed Graft Function | 1 | 2024 | 4 | 0.210 |
Why?
|
| B-Cell Maturation Antigen | 1 | 2024 | 11 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 5 | 2024 | 2507 | 0.210 |
Why?
|
| Graft vs Host Disease | 2 | 2020 | 631 | 0.210 |
Why?
|
| Intensive Care Units | 4 | 2025 | 497 | 0.210 |
Why?
|
| Graft Survival | 2 | 2024 | 454 | 0.210 |
Why?
|
| Genetics, Population | 1 | 2025 | 184 | 0.210 |
Why?
|
| Femoral Fractures | 1 | 2024 | 33 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2024 | 187 | 0.210 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 49 | 0.210 |
Why?
|
| Cold Ischemia | 1 | 2024 | 28 | 0.210 |
Why?
|
| Quinolines | 1 | 2024 | 111 | 0.210 |
Why?
|
| Female | 27 | 2025 | 68330 | 0.210 |
Why?
|
| Sepsis | 3 | 2024 | 493 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 649 | 0.200 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2023 | 74 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2024 | 167 | 0.200 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 74 | 0.200 |
Why?
|
| Orthopedics | 1 | 2024 | 76 | 0.200 |
Why?
|
| Ivermectin | 1 | 2022 | 8 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 1705 | 0.190 |
Why?
|
| Hip Fractures | 1 | 2023 | 67 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 578 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2025 | 226 | 0.190 |
Why?
|
| Lymphoma | 2 | 2017 | 319 | 0.180 |
Why?
|
| Budesonide | 1 | 2021 | 19 | 0.180 |
Why?
|
| Data Accuracy | 1 | 2021 | 30 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2023 | 111 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 285 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2024 | 147 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 249 | 0.170 |
Why?
|
| Information Storage and Retrieval | 1 | 2021 | 61 | 0.170 |
Why?
|
| Hospitals | 3 | 2024 | 428 | 0.170 |
Why?
|
| COS Cells | 2 | 2018 | 244 | 0.170 |
Why?
|
| Fungemia | 1 | 2020 | 21 | 0.170 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2020 | 12 | 0.170 |
Why?
|
| Risk Factors | 8 | 2025 | 10555 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 539 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2025 | 6214 | 0.170 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2020 | 8 | 0.170 |
Why?
|
| Neuromuscular Blockade | 1 | 2020 | 6 | 0.170 |
Why?
|
| Neostigmine | 1 | 2020 | 5 | 0.170 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 27 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2023 | 330 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2020 | 32 | 0.160 |
Why?
|
| Tissue Donors | 1 | 2024 | 491 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2025 | 4954 | 0.160 |
Why?
|
| Gram-Negative Bacteria | 1 | 2020 | 70 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 32 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 259 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 2036 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 200 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2020 | 90 | 0.160 |
Why?
|
| Propranolol | 1 | 2020 | 111 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 370 | 0.150 |
Why?
|
| HeLa Cells | 2 | 2018 | 684 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 290 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1234 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 457 | 0.150 |
Why?
|
| Unrelated Donors | 1 | 2019 | 72 | 0.150 |
Why?
|
| Cell Line | 3 | 2018 | 2560 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 288 | 0.150 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 53 | 0.150 |
Why?
|
| ROC Curve | 3 | 2025 | 587 | 0.140 |
Why?
|
| Zearalenone | 1 | 2018 | 6 | 0.140 |
Why?
|
| Resorcinols | 1 | 2018 | 7 | 0.140 |
Why?
|
| Dioxoles | 1 | 2018 | 12 | 0.140 |
Why?
|
| Melphalan | 1 | 2018 | 43 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 560 | 0.140 |
Why?
|
| Health Education | 1 | 2020 | 222 | 0.140 |
Why?
|
| Lactones | 1 | 2018 | 40 | 0.140 |
Why?
|
| Cytological Techniques | 1 | 2017 | 17 | 0.140 |
Why?
|
| Heart Arrest | 1 | 2022 | 362 | 0.140 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 152 | 0.140 |
Why?
|
| Siblings | 1 | 2019 | 202 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2020 | 211 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 495 | 0.140 |
Why?
|
| Acetylation | 1 | 2018 | 181 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 164 | 0.140 |
Why?
|
| Benzamides | 1 | 2018 | 120 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1728 | 0.130 |
Why?
|
| Etanercept | 1 | 2017 | 44 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 381 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 191 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 871 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 372 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 66 | 0.130 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 171 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 59 | 0.130 |
Why?
|
| Bacteremia | 1 | 2020 | 420 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 106 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 658 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2020 | 315 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2018 | 585 | 0.120 |
Why?
|
| Mitochondrial Dynamics | 1 | 2016 | 49 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2017 | 132 | 0.120 |
Why?
|
| Autophagy | 2 | 2017 | 404 | 0.120 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 150 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 320 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 157 | 0.110 |
Why?
|
| Endothelium | 1 | 2015 | 63 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 272 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1137 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 458 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 161 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 422 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 531 | 0.110 |
Why?
|
| Hospitals, University | 2 | 2025 | 103 | 0.110 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 187 | 0.110 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 337 | 0.110 |
Why?
|
| Logistic Models | 2 | 2016 | 1779 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 684 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2014 | 90 | 0.110 |
Why?
|
| Illinois | 2 | 2024 | 16 | 0.100 |
Why?
|
| Plasmacytoma | 1 | 2013 | 10 | 0.100 |
Why?
|
| Veterans | 1 | 2024 | 1741 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2014 | 415 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 422 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3066 | 0.090 |
Why?
|
| Phenotype | 1 | 2021 | 4304 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 217 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 9665 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2018 | 4472 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2024 | 301 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 730 | 0.080 |
Why?
|
| Blood Culture | 2 | 2021 | 36 | 0.080 |
Why?
|
| Organ Transplantation | 1 | 2013 | 174 | 0.080 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 481 | 0.080 |
Why?
|
| Exercise | 3 | 2024 | 839 | 0.080 |
Why?
|
| Reoperation | 2 | 2024 | 818 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 273 | 0.080 |
Why?
|
| Comorbidity | 1 | 2015 | 1559 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2015 | 757 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1584 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 2855 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2024 | 12546 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2024 | 1047 | 0.070 |
Why?
|
| Mice | 4 | 2018 | 17596 | 0.070 |
Why?
|
| United States | 3 | 2024 | 11310 | 0.070 |
Why?
|
| Animals | 5 | 2024 | 33051 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 815 | 0.070 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 304 | 0.060 |
Why?
|
| Endoglin | 2 | 2015 | 31 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2024 | 16 | 0.060 |
Why?
|
| Latin America | 1 | 2025 | 95 | 0.060 |
Why?
|
| Drug Industry | 1 | 2024 | 47 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 174 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2024 | 233 | 0.050 |
Why?
|
| Culturally Competent Care | 1 | 2024 | 49 | 0.050 |
Why?
|
| Knee | 1 | 2024 | 19 | 0.050 |
Why?
|
| Linkage Disequilibrium | 1 | 2025 | 313 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 158 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2024 | 145 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2024 | 130 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2024 | 133 | 0.050 |
Why?
|
| Haplotypes | 1 | 2025 | 525 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 123 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 152 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2020 | 1312 | 0.050 |
Why?
|
| Frailty | 1 | 2025 | 131 | 0.050 |
Why?
|
| Outpatients | 1 | 2024 | 254 | 0.050 |
Why?
|
| Hypertension | 2 | 2024 | 1301 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 29 | 0.050 |
Why?
|
| Knee Joint | 1 | 2024 | 163 | 0.050 |
Why?
|
| Vital Signs | 1 | 2022 | 26 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 152 | 0.050 |
Why?
|
| Adolescent | 2 | 2024 | 20002 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8347 | 0.050 |
Why?
|
| Endothelial Cells | 2 | 2017 | 501 | 0.050 |
Why?
|
| Time Factors | 2 | 2022 | 6134 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2025 | 742 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 1536 | 0.040 |
Why?
|
| Life Style | 1 | 2024 | 433 | 0.040 |
Why?
|
| Chicago | 1 | 2021 | 21 | 0.040 |
Why?
|
| Organ Dysfunction Scores | 1 | 2021 | 52 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2024 | 406 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2021 | 133 | 0.040 |
Why?
|
| DNA Topoisomerase IV | 1 | 2020 | 11 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 244 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 94 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2020 | 25 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2022 | 439 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 555 | 0.040 |
Why?
|
| Asia, Western | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 119 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2025 | 1193 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 181 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2024 | 553 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 12771 | 0.040 |
Why?
|
| Software | 1 | 2025 | 711 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 306 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2015 | 14347 | 0.040 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 83 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 396 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2020 | 51 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 2225 | 0.040 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 18 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 565 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2101 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 336 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 154 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2018 | 24 | 0.040 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 2 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 189 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2020 | 466 | 0.030 |
Why?
|
| Genome, Human | 1 | 2025 | 1279 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2017 | 40 | 0.030 |
Why?
|
| Critical Care | 1 | 2023 | 668 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2017 | 74 | 0.030 |
Why?
|
| Binding Sites | 1 | 2020 | 1185 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2018 | 99 | 0.030 |
Why?
|
| Magnoliaceae | 1 | 2017 | 1 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 330 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2017 | 283 | 0.030 |
Why?
|
| New York City | 1 | 2016 | 63 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 550 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 49 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 412 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 2065 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 318 | 0.030 |
Why?
|
| Methotrexate | 1 | 2018 | 313 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 184 | 0.030 |
Why?
|
| Superoxides | 1 | 2016 | 129 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 923 | 0.030 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2016 | 59 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 970 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2746 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 691 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 132 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2015 | 30 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 266 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1184 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3907 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2020 | 546 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 379 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 512 | 0.030 |
Why?
|
| Child | 1 | 2015 | 25101 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 477 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 439 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3586 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 515 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 898 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 228 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5114 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 31 | 0.030 |
Why?
|
| Prognosis | 1 | 2024 | 4772 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 2591 | 0.030 |
Why?
|
| Zebrafish | 1 | 2017 | 402 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 492 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 946 | 0.030 |
Why?
|
| DNA Primers | 1 | 2015 | 602 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 275 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1048 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 162 | 0.030 |
Why?
|
| Anticholesteremic Agents | 1 | 2016 | 239 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 338 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 105 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2883 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 596 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 399 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 541 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1166 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 1207 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1364 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1100 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1374 | 0.020 |
Why?
|
| Obesity | 1 | 2024 | 2332 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3498 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 604 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 523 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2013 | 53 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 456 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1222 | 0.020 |
Why?
|
| Protein Binding | 1 | 2016 | 1661 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2016 | 1082 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 581 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 445 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 901 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2016 | 761 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2757 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3222 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1654 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3251 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2789 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2893 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 873 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 4504 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3695 | 0.010 |
Why?
|